Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?

The treatment of multiple myeloma (MM) has evolved over the past decade, yet it remains a chronic disease. Several trials of 4-drug induction regimens have resulted in deepening of disease response. With the emergence of multidrug regimens, questions have arisen regarding the role of autologous stem cell transplant (ASCT) in MM therapy and available treatment options after ASCT. Clinicians have also continued to improve the efficacy of maintenance therapies. In transplant-ineligible patients, the phases of treatment are less distinct; however, several regimens have demonstrated efficacy in this clinical setting. Future research should focus on individualizing treatment approaches.

Automated summary

The treatment of multiple myeloma has advanced in the past decade, but it remains a chronic disease. Customized treatment approaches are needed for different patients. Combination drug regimens can deepen disease response, and further research is required on treatment options post-autologous stem cell transplant.